Literature DB >> 15857988

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.

Dimitri Lavillette1, Yoann Morice, Georgios Germanidis, Peggy Donot, Alexandre Soulier, Emanuil Pagkalos, Georgios Sakellariou, Liliane Intrator, Birke Bartosch, Jean-Michel Pawlotsky, François-Loïc Cosset.   

Abstract

The factors leading to spontaneous clearance of hepatitis C virus (HCV) or to viral persistence are elusive. Understanding virus-host interactions that enable acute HCV clearance is key to the development of more effective therapeutic and prophylactic strategies. Here, using a sensitive neutralization assay based on infectious HCV pseudoparticles (HCVpp), we have studied the kinetics of humoral responses in a cohort of acute-phase patients infected during a single nosocomial outbreak in a hemodialysis center. The 17 patients were monitored for the spontaneous outcome of HCV infection for 6 months before a treatment decision was made. Blood samples were taken frequently (15 +/- 4 per patient). Phylogenetic analysis of the predominant virus(es) revealed infection by only one of two genotype 1b strains. While all patients seroconverted, their sera induced two opposing effects in HCVpp infection assays: inhibition and facilitation. Furthermore, the ability of sera to facilitate or inhibit infection correlated with the presence of either infecting HCV strain and divided the patients into two groups. In group 1, the progressive emergence of a relatively strong neutralizing response correlated with a fluctuating decrease in high initial viremia, leading to control of viral replication. Patients in group 2 failed to reduce viremia within the acute phase, and no neutralizing responses were detected despite seroconversion. Strikingly, sera of group 2, as well as naive sera, facilitated infection by HCVpp displaying HCV glycoproteins from different genotypes and strains, including those retrieved from patients. These results provide new insights into the mechanisms of viral persistence and immune control of viremia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857988      PMCID: PMC1091689          DOI: 10.1128/JVI.79.10.6023-6034.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA.

Authors:  A A Kolykhalov; E V Agapov; K J Blight; K Mihalik; S M Feinstone; C M Rice
Journal:  Science       Date:  1997-07-25       Impact factor: 47.728

2.  Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection.

Authors:  Z Prohászka; J Nemes; T Hidvégi; F D Tóth; K Kerekes; A Erdei; J Szabó; E Ujhelyi; N Thielens; M P Dierich; P Späth; B Ghebrehiwet; H Hampl; J Kiss; G Arlaud; G Füst
Journal:  AIDS       Date:  1997-07       Impact factor: 4.177

3.  Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children.

Authors:  G Adams; S Kuntz; G Rabalais; D Bratcher; C H Tamburro; G J Kotwal
Journal:  Pediatr Infect Dis J       Date:  1997-05       Impact factor: 2.129

Review 4.  Enhancing antibodies in HIV infection.

Authors:  G Füst
Journal:  Parasitology       Date:  1997       Impact factor: 3.234

5.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up.

Authors:  J M Christie; C J Healey; J Watson; V S Wong; M Duddridge; N Snowden; W M Rosenberg; K A Fleming; H Chapel; R W Chapman
Journal:  Clin Exp Immunol       Date:  1997-10       Impact factor: 4.330

7.  A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures.

Authors:  Y K Shimizu; H Igarashi; T Kiyohara; T Cabezon; P Farci; R H Purcell; H Yoshikura
Journal:  Virology       Date:  1996-09-15       Impact factor: 3.616

8.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.

Authors:  H M Diepolder; R Zachoval; R M Hoffmann; E A Wierenga; T Santantonio; M C Jung; D Eichenlaub; G R Pape
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

9.  Effect of immune globulin on the prevention of experimental hepatitis C virus infection.

Authors:  K Krawczynski; M J Alter; D L Tankersley; M Beach; B H Robertson; S Lambert; G Kuo; J E Spelbring; E Meeks; S Sinha; D A Carson
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

10.  Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

View more
  102 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

2.  A milestone for hepatitis C virus research: a virus generated in cell culture is fully viable in vivo.

Authors:  Jens Bukh; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

3.  Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.

Authors:  Kathleen McCaffrey; Irene Boo; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

Review 4.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 5.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

Review 6.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

7.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

9.  Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts.

Authors:  Lisa Cukierman; Laurent Meertens; Claire Bertaux; Francis Kajumo; Tatjana Dragic
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 10.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.